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Background: Multiple variables influencing the sustained virologic response (SVR) in 
chronic hepatitis C have been evaluated. One of them is genetic polymorphism near the 
IL28B gene. 
Objectives: The aim of this study was to evaluate the influence of IL28B genotypes on SVR 
rates in a group of patients with chronic hepatitis C from the western part of Romania.
Patients and Methods: A retrospective study was performed in 107 consecutive patients, 
previously treated with standard-of-care medication for chronic hepatitis C, identified 
from the databases of 2 centers. Patient demographics, viral load before treatment and 
at 12, 24, and 72 weeks from the treatment start, and IL28B genotype were evaluated.
Results: Among the 107 patents in the study group, 54 patients had SVR (50.5%), and 62 
(57.9%) showed a complete early virologic response (cEVR). The SVR rates according to 
IL28B genotype were as follows: 73.1% in patients with genotype C/C, 40.9% in those with 
genotype C/T, and 57.1% in those with genotype T/T (i.e., 73.1% among patients with the 
C/C genotype vs. 43.7% among those with non-C/C genotypes; P = 0.0126). The cEVR rates 
were 80.8% in patients with the C/C genotype vs. 51.2% in those with non-C/C genotypes 
(P = 0.011). 
Conclusions: In our cohort of 107 Caucasian HCV patients, the SVR rate was 50.5% with 
standard-of-care treatment. The SVR rate was directly related to the IL28B genotype: 73.1% 
in the C/C genotype vs. 43.7% in non-C/C genotypes (P = 0.0126). 
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 Implication for health policy/practice/research/medical education:
Chronic C hepatitis is a global healthcare problem, affecting approximately 3% of world population, with sustained virologic re-
sponse rates after treatment ranging from 34 to 61%. The genetic polymorphism near the IL28B gene, encoding interferon-lamb-
da-3, is associated with different response rates to treatment. Reading this article is recommended to all interested in this subject.
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1. Background
Chronic C hepatitis is a global healthcare problem, af-
fecting approximately 3% of the world population (1), 
and is an endemic disease in some areas (2). The number 
of patients requiring treatment for this disease is increas-
ing; therefore, the treatment costs, at the global level, are 
huge. Reference studies report sustained virologic response 
(SVR) rates ranging from 34% to 61% in patients infected 
with genotype 1 HCV, in connection with ethnicity, gen-
der, age, severity of fibrosis, or viral load (3-5). Multiple 
factors influencing SVR rates have been evaluated, to find 
the best candidates to achieve viral clearance. Recently, 
several papers reported that a genetic polymorphism 
near the IL28B gene, encoding interferon-lambda-3, is 976 SVR and IL28B genotype Sporea I et al.
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associated with an approximately 2-fold change in treat-
ment response (6-8). Several previous studies showed 
that SVR rates vary in patients according to their ethnic-
ity, with lower rates in the Afro-American population fol-
lowed by Caucasians, and with the best results occurring 
in Asian populations. These results can be possibly ex-
plained by genetic polymorphisms in the IL28B gene in 
different populations. In Romania, 99.7% of HCV patients 
are infected with genotype 1, the most difficult to treat 
(9). A recently published epidemiological study showed 
that 3.23% of the Romanian population is chronically in-
fected with HCV (10). Thus, considerable financial effort 
is needed to treat this large number of patients; there-
fore, if very good predictors for SVR are found, different 
approaches should be used for these patients. New drugs 
for the treatment of chronic hepatitis C (telaprevir or 
boceprevir) are expected on the market in the next year, 
with better therapeutic results (compared to pegylated 
interferon [PegIFN] and ribavirin alone), but probably 
with high financial impact. New therapeutic strategies 
for the stratification of patients may therefore be needed 
in order to increase SVR rates with minimal cost increase.
2. Objectives
The aim of our study was to identify a correlation, if any, 
between the IL28B genotype and SVR rates in a group of 
patients previously treated with PegIFN and ribavirin 
for chronic hepatitis C in the western part of Romania 
(Banat Region). 
3. Patients and Methods
We performed a retrospective study on 107 consecu-
tive unrelated Caucasian patients previously treated 
for chronic hepatitis C with standard of care medica-
tion: PegIFN α-2a (180 µg/week) + ribavirin (1,000 mg/
day for patients with body weight < 75 kg; 1,200 mg/day 
for patients with body weight > 75 kg) for 48 weeks; or 
PegIFN α-2b (1.5 µg/kg/week) + ribavirin (800 mg/day for 
patients with body weight < 65 kg; 1,000 mg/day for pa-
tients with body weight 65–85 kg; 1,200 mg/day for pa-
tients with body weight > 85 kg) for 48 weeks. Clinically 
significant dose reductions of either PegIFN or ribavirin 
were not needed in any of the patients. Patients who re-
ceived treatment starting from January 2009 and who 
finished the treatment regimen before 31st of May 2010 
were identified from the databases of two centers. We 
contacted all patients who underwent treatment in this 
period and included all who accepted to participate in 
the study. Each patient’s data were collected in a specially 
designed study file that included patient demographics, 
body mass index (BMI), severity of fibrosis evaluated on 
liver biopsy by the Metavir score (available in 102/107 pa-
tients), viral load before treatment, at 12 weeks of treat-
ment (to evaluate the early virologic response, EVR), at 
24 weeks of treatment (in patients in which only partial 
EVR was achieved), and at 72 weeks from the start of treat-
ment (to evaluate the SVR). EVR was defined as undetect-
able viral load or a decrease in viral load by at least two 
log10 after 12 weeks of treatment, compared with base-
line. Complete EVR (cEVR) was defined as undetectable 
viral load after 12 weeks of treatment. Partial EVR (pEVR) 
was defined as a decrease in viral load by at least two 
log10 compared to baseline after 12 weeks of treatment, 
but not aviremic. SVR was defined as undetectable viral 
load 24 weeks after the end of treatment. Blood samples 
were collected from each patient for IL28B genotyping, 
which was performed in the same unit, by real-time PCR 
(in-house method). Blood specimens were genotyped for 
IL-28B rsC12979860T on a LightCycler 1.5 Thermocycler 
(Roche, Mannheim, Germany). DNA was isolated from 
EDTA-whole blood using a fully automated purification 
device (GenoXtract) and the appropriate blood extrac-
tion cartridges (Hain Lifescience, Nehren, Germany). 
Following PCR amplification, the IL28B dimorphism was 
identified with a 6-carboxy fluorescein (FAM)-labeled 
HyBeacon (11) probe, which creates melting peaks at 
defined temperatures that are characteristic to specific 
DNA structures. Quantification of the HCV-RNA was done 
using the Cobas AmpliPrep/ Cobas TaqMan HCV (12) test 
(Roche) according to the recommendations of the man-
ufacturer. Because a previous study performed in Roma-
nia showed that 99.7% of Romanian HCV patients are 
infected with genotype 1 (9), we decided not to perform 
HCV genotyping in our study group (in order to lower 
the costs). All the patients consented to participate to 
the study, which was approved by the local Ethical Com-
mittee. The data we obtained from our patients were col-
lected in a Microsoft Excel file. Statistical analyses were 
performed using the Microsoft Excel 2007 and GraphPad 
Prism 5 programs. For the statistical study of quantita-
tive variables, the mean and standard deviation were 
calculated. Unpaired t-test and one-way ANOVA test were 
used to compare means. Chi square test and Fisher’s ex-
act test were used to compare proportions. 
4. Results
The study group included 107 patients, 63 (58.9%) 
women and 44 (41.1%) men, with a mean age of 53.4 ± 
9.6 years. All patients were Caucasians. The mean BMI of 
the patients from the study group was 27.3 ± 3.9 kg/m2; 
32.7% of the patients were of normal weight, 43.9% were 
overweight, and 23.4% were obese. The baseline viral load 
was < 600,000 IU/mL in 31.8% of patients, and the mean 
liver fibrosis (Metavir) score of the same group was 2.4 ± 
0.6 (Table 1). From the study group, 54 patients achieved 
SVR (50.5%), while 53 (49.4%) did not (non-responders 
and relapsers). The frequencies of IL28B genotypes in 
the study group were as follows: 26 (24.3%) patients were 
of genotype C/C, 67 (62.6%) were of genotype C/T, and 14 
(13.1%) were of genotype T/T. Table 2 summarizes patient 
characteristics in each IL28B genotype subgroup: mean 
age, gender distribution, mean BMI, mean viral load at 
baseline, number of patients with baseline viral load < 
600,000 IU/mL, and mean liver fibrosis. The mean base-
line viral load in each IL28B genotype subgroup was as 977 SVR and IL28B genotype Sporea I et al.
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follows: 2,250,100.5 IU/mL in the C/C group, 2,309,536.5 
IU/mL in the C/T group, and 1,017,544.2 IU/mL in the T/T 
group. The baseline viral load in the T/T group was signif-
icantly lower than that in the C/C group (P = 0.0147) and 
the C/T group (P = 0.0084). The mean baseline viral loads 
in the C/C and C/T groups were not significantly differ-
ent (P = 0.65). Further, the proportion of patients with a 
low baseline viral load (< 600.000 IU/mL) was highest in 
the T/T group (64.3%) compared to the C/C (19.2%) and C/T 
(28.4%) groups. There were no statistically significant dif-
ferences between the three IL28B subgroups regarding 
the following parameters: mean fibrosis severity evalu-
ated by the Metavir score (P = 0.8162 by one-way ANOVA 
test), mean BMI (P = 0.661 by one-way ANOVA test), mean 
age (P = 0.2388 by one-way ANOVA test), and the ratio 
of women to men (P = 0.358 by Chi-square test). The re-
sponse rates in our study group stratified according to 
the IL28B genotype are presented in Table 3 (one of the 107 
patients was noncompliant to treatment, despite the fact 
that he had a cEVR, and was excluded from the analysis). 
The occurrence of a complete early virologic response 
(cEVR) was significantly higher in the C/C genotype 
group (80.8%; 21/26 patients) than in the non-C/C geno-
types (C/T + T/T; 51.2%; 41/80 patients; P = 0.011 by Fisher’s 
exact test). On the other hand, SVR was achieved in 73.1% 
(19/26) of the C/C patients vs. 43.7% (35/80) of the non-C/C 
patients (P = 0.0126 by Fisher’s exact test).
Value
Patients, No. 107
Gender, No. (%)
Women
Men
63 (58.9)
44 (41.1)
Age, y, mean ± SD a 53.4 ± 9.6
BMI b, kg/m 2, mean ± SD 27.3 ± 3.9b
Normal weight c, No. (%) 35 (32.7)
Overweight d, No. (%) 47 (43.9)
Obese e, No. (%) 25 (23.4)
Baseline viral load, IU/mL
< 600,000
≥ 600,000
34 (31.8)
73 (68.2)
Liver fibrosis (Metavir) score, mean ± SD 2.4 ± 0.6
Distribution of liver fibrosis f, No. (%)  
F1 a
F2
F3
F4
5 (4.9)
49 (48)
42 (41.2)
6 (5.9)
 Table 1. Patient Characteristics in the Study Group
a Abbreviations: BMI, body mass index; F, fibrosis; SD, standard deviation
b range 20.5–39.1 kg/m 2
c < 25 kg/m 2
d 25–29.9 kg/m 2
e ≥ 30 kg/m 2
f 102 patients with liver biopsy, evaluated according to the Metavir score
C/C Genotype C/T Genotype T/T Genotype
Age, y, mean ± SD 54.2 ± 7.4  53.9 ± 10.1 49.7 ± 10.3 
Patients, No. 26 67 14
Female, No. (%)  18 (69.2) 36 (53.7) 9 (64.3)
BMI a, kg/m 2, mean ± SD 26.6 ± 2.9 27.7 ± 4.2 26.9 ± 4.1
Viral load at baseline, IU/mL, mean ± SD a 2,250,100.5 ± 1,743,166 2,309,536.5 ± 2,420,368 1,017,544.2 ± 1,462,900.7
Patients with baseline viral load < 600,000 
IU/mL, No. (%)
5 (19.2) 19 (28.4) 9 (64.3)
Liver fibrosis b, mean ± SD 2.4 ± 0.6 c 2.5 ± 0.7 d 2.3 ± 0.5 e
 Table 2. Patient Characteristics in Each IL28B Genotype Subgroup
a Abbreviations: BMI, body mass index; SD, standard deviation
b in cases with liver biopsy – Metavir score
c 26 patients
d 63 patients
e 13 patients
C/C Genotype  C/T Genotype  T/T Genotype 
Patients, No. 26 66 14
SVR a, No. (%) 19 (73.1) 27 (40.9) 8 (57.1)
Non-SVR, No. (%) 7 (26.9) 39 (59.1) 6 (42.9)
cEVR a, No. (%) 21 (80.8) 34 (50.7) 7 (50)
EVR a (cEVR + pEVR a), No. (%) 26 (100) 60 (89.5) 12 (85.7)
Table 3. Relationship Between IL28B Genotype and Response to Treatment Rates (cEVR, EVR and SVR) in the Study Group (106 patients)
a Abbreviations: cEVR, complete early virologic response; EVR, early virologic response; pEVR, partial early virologic response; SVR, sustained virologic 
response978 SVR and IL28B genotype Sporea I et al.
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5. Discussion
Several papers have reported that genetic polymor-
phisms near the IL28B gene, encoding interferon-lamb-
da-3, influence the response to treatment in chronic 
hepatitis C (6-8). In a study performed on 871 patients 
with Caucasian ancestry (13), the C/C genotype was found 
in 39%, C/T in 49%, and T/T in 12% of the study group. Con-
sistent with these findings, the majority of the patients 
in the present study were of genotype C/T (62.8%), fol-
lowed by 24.5% with genotype C/C, and a small propor-
tion (12.7%) with genotype TT. Studies originating from 
different parts of Asia indicate that a large proportion of 
the Asian population is of IL28B genotype C/C; this ex-
plains the high SVR rates in patients with chronic hepati-
tis C in this area (14, 15). The most important aspect of 
IL28B genotyping is its relationship with SVR rates fol-
lowing standard-of-care treatment (PegIFN plus ribavi-
rin). Two years ago, a paper published in Nature by Ge et 
al. (6) showed that in patients of European ancestry, the 
C/C genotype is associated with a 2-fold (95% confidence 
interval 1.8–2.3) greater rate of SVR than in the T/T geno-
type. Another study (16) showed that in patients with the 
C/C genotype, the SVR was 69%, compared to 33% in those 
with the C/T genotype and 27% in those with the T/T geno-
type. In the same study, important differences were ob-
served regarding several other parameters: the rapid vi-
rologic response (RVR; 28%, 5%, and 5% in patients with 
the C/C, C/T, and T/T genotypes, respectively); EVR (97%, 
72%, and 68% in patients with the C/C, C/T, and T/T geno-
types, respectively); the end-of-treatment response (EOT; 
92%, 56%, and 51% in patients with the C/C, C/T, and T/T 
genotypes, respectively); relapse rates (14%, 27%, and 31% 
in patients with the C/C, C/T, and T/T genotypes, respec-
tively). Another group tested if the IL28B genotype could 
be used to tailor treatment duration according to base-
line viral load and virologic response during treatment 
in genotype 1 HCV patients (17). In this multicenter Ger-
man study, 398 treatment-naive HCV genotype-1 patients 
were enrolled and treated with PegIFN and ribavirin. 
Overall SVR rates of 55% and 48% were obtained in pa-
tients treated with individualized durations and 48 
weeks standard duration, respectively. The IL28B geno-
type was available for 305 of the 398 patients who com-
pleted therapy. The SVR rate in patients who completed 
the therapy was 65%. Of the non-responders, 96% (65/68) 
were of IL28B genotypes C/T and T/T. SVR was achieved in 
85%, 58%, and 46% of patients with C/C, C/T, and T/T IL28B 
genotypes, respectively. However, the overall relapse 
rates were similar for C/C, C/T, and T/T IL28B genotypes 
(13%, 19%, and 21%, respectively). A study by Stättermayer 
and co-workers (18) evaluated the role of IL28B genotypes 
on the EVR in 682 treatment-naïve patients, including 372 
patients infected with HCV genotype (GT) 1, 208 patients 
with GT 2/3, and 102 patients with GT 4. Patients were 
treated with 180 µg PegIFN α-2a, and 400 or 800 mg (GT 
2/3, depending on the protocol) or 1000–1200 mg (GT 1/4) 
ribavirin per day, the duration of treatment being 24 (GT 
2/3) or 24–72 weeks (GT 1/4). This study showed that the 
viral load decrease 24 hours after the first dose of interferon 
in patients of GT 1/4 was greater in carriers of the C/C than of 
the T/T allele, and that patients with the C/C allele also had 
higher rates of RVR (GT 1, 38.3% vs. 11.6%; GT 4, 76.5% vs. 23.5%; 
both P < 0.001) and SVR (GT 1, 79.1% vs. 43.2%; GT 4, 85.3% vs. 
44.1%; both P < 0.001). The conclusion of this study was that 
an early virologic response to PegIFN and ribavirin is more 
likely among carriers of the C/C IL28B polymorphism, which 
might underlie their high rate of SVR, and that IL28B geno-
type determination as well as the presence of an RVR 
might be used in future studies of patients with hepatitis 
C virus genotypes 1 or 4. Studies regarding the relation-
ship between the IL28B genotype and the results of treat-
ment in patients infected with HCV GT 2 and 3 showed 
that the influence of the IL28B genotype on the SVR in 
these patients is less important (18-20). Currently, there 
are several published papers regarding the relationship 
between the IL28B genotype and SVR (also RVR or EVR) in 
Caucasian patients infected with HCV genotype 1. In the 
German study previously mentioned, the overall SVR af-
ter 48 weeks, with standard duration of treatment, was 
48% (17). In our study in the western part of Romania, 
with the same standard 48-week treatment duration, the 
SVR was 50.5 %, similar to the German study. Additionally, 
in a previously published study from our group that in-
cluded 582 HCV genotype 1 patients from 2 Romanian 
centers, in an intention-to-treat analysis, the SVR rate was 
51.9% (5). The most important aspect of IL28B genotyping 
is the fact that we can predict the chance of SVR (and, ac-
cording to some studies, the chance of RVR and EVR), 
based on the IL28B genotype of the patient. A study by 
Thompson et al. (16) showed that patients with the C/C 
genotype achieved an SVR rate of 69%, as compared to 33% 
and 27% in those with the C/T and T/T genotypes, respec-
tively. In a study by Sarrazin et al. (17), SVR was achieved in 
85%, 58%, and 46% of patients with the C/C, C/T and T/T 
IL28B genotypes, respectively. In the group of patients 
from the Stättermayer study (18), the SVR rate was 79.1% in 
the C/C genotype vs. 43.2% in patients with T/T genotype. 
In our group, similar results were obtained: a 73.1% SVR 
rate in patients of genotype C/C, 40.9% in patients of gen-
otype C/T, and 57.1% in patients of genotype T/T (or 73.1% in 
C/C vs. 43.7% in non-C/C patients; P = 0.0126). On the other 
hand, in our study, the baseline viral load in the T/T group 
(1,017,544.2 IU/mL) was significantly lower than in the C/C 
(P = 0.0147) and C/T (P = 0.0084) groups, and the propor-
tion of patients with a low baseline viral load (< 600.000 
IU/mL) was the highest in the T/T group (64.3%), com-
pared to the C/C (19.2%) and C/T (28.4%) groups. These dif-
ferences, and the small number of patients in the T/T 
group, may explain the high SVR in this group (SVR = 
57.1%). Lagging et al. (21) carried out a study involving 253 
Caucasian patients, in whom they correlated the occur-
rence of variants at 3 such SNPs (rs12979860, rs12980275, 
and rs8099917) with pretreatment plasma IP-10 and HCV 
RNA levels throughout therapy. They demonstrated that 
in genotype 1-infected patients, baseline IP-10 and a C 
genotype at rs12979860 independently predicted the first 979 SVR and IL28B genotype Sporea I et al.
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phase of viral decline and RVR, which in turn indepen-
dently predicted SVR. Thus, among genotype 1-infected 
patients, homozygous carriers of the 3 favorable IL28B al-
leles had significantly more pronounced first phase viral 
decline than did patients carrying the risk alleles (mean, 
2.0, 0.9, and 0.6 log10 IU/mL for rs12979860 CC, CT, and TT, 
1.8, 0.9, and 0.7 log10 IU/mL for rs12980275 AA, AG, and TT, 
respectively, and 1.4, 0.8, and 0.6 log10 IU/mL for rs8099917 
TT, TG, and GG respectively; P = 0.0001 for all 3 SNPs; 
Kruskal-Wallis test). Furthermore, among HCV genotype 
1-infected carriers of the favorable C, A, or T alleles, IP-10 
levels below 150 pg/mL significantly predicted higher 
rates of RVR (62%, 53%, and 39%) and SVR (85%, 76%, and 75% 
respectively). On the other hand, patients carrying fa-
vorable SNP genotypes had a higher baseline viral load 
than those carrying unfavorable variants. The authors 
concluded that concomitant assessment of pretreat-
ment IP-10 levels and IL28B-related SNPs augments the 
prediction of RVR and the final therapeutic outcome. 
Thus, from the perspective of triple therapy for HCV 
chronic infection that is expected to enter soon in cur-
rent clinical practice, testing for the IL28B genotype of 
the patient seems to be reasonable, in order to make a 
decision regarding the treatment. In the C/C genotype, 
the high SVR rates possibly justify treating these patients 
with double therapy (PegIFN + ribavirin) only, and for the 
C/T and T/T genotypes, triple therapy seems to be the best 
option.
In our cohort of 107 Caucasian patients with chronic 
hepatitis due to HCV, the SVR rate was 50.5% with stan-
dard-of-care treatment (PegIFN and ribavirin for 48 
weeks). The SVR rate was directly related to the IL28B 
genotype: 73.1% in the C/C IL28B genotype vs. 43.7% in non-
C/C patients (P = 0.0126). Further treatment strategies for 
chronic hepatitis C can be designed based on the IL28B 
genotype, in order to increase the SVR rate.
Acknowledgement
None declared.
Financial Disclosure
None declared.
Funding/Support
This study was supported by a grant from Merck Sharp 
and Dohme Romania.
References
1.  Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C 
virus infection. Lancet Infect Dis. 2005;5(9):558-67.
2.  World Health Organization. Hepatits C. Fact sheet N°164. WHO; 
2009 [updated 2011 June]; Available from: www.who.int/mediacen-
tre/factsheets/fs164/en/.
3.  McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone 
J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of 
hepatitis C infection. N Engl J Med. 2009;361(6):580-93.
4.  Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman 
M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin 
compared with interferon alfa-2b plus ribavirin for initial 
treatment of chronic hepatitis C: a randomised trial. Lancet. 
2009;358(9286):958-65.
5.  Sporea I, Sirli R, Curescu M, Gheorghe L, Popescu A, Bota S, et al. 
Outcome of antiviral treatment in patients with chronic geno-
type 1 HCV hepatitis. A retrospective study in 507 patients. J Gas-
trointestin Liver Dis. 2010;19(3):261-4.
6.  Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et 
al. Genetic variation in IL28B predicts hepatitis C treatment-
induced viral clearance. Nature. 2009;461(7262):399-401.
7.  Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. 
Genetic variation in IL28B is associated with chronic hepatitis C 
and treatment failure: a genome-wide association study. Gastro-
enterology. 2010;138(4):1338-45, 45 e1-7.
8.  Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, 
Applegate T, et al. Potential role for interleukin-28B genotype in 
treatment decision-making in recent hepatitis C virus infection. 
Hepatology. 2010;52(4):1216-24.
9.  Grigorescu M. HCV genotype 1 is almost exclusively present in 
Romanian patients with chronic hepatitis C. J Gastrointestin Liver 
Dis. 2009;18(1):45-50.
10.  Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Smira G, Regep L. The 
prevalence and risk factors of hepatitis C virus infection in adult 
population in Romania: a nationwide survey 2006 - 2008. J Gas-
trointestin Liver Dis. 2010;19(4):373-9.
11.  French DJ, McDowell DG, Debenham P, Gale N, Brown T. HyBea-
con probes for rapid DNA sequence detection and allele discrim-
ination. Methods Mol Biol. 2008;429:171-85.
12.  Bossler A, Gunsolly C, Pyne MT, Rendo A, Rachel J, Mills R, et al. 
Performance of the COBAS(R) AmpliPrep/COBAS TaqMan(R) au-
tomated system for hepatitis C virus (HCV) quantification in a 
multi-center comparison. J Clin Virol. 2011;50(2):100-3.
13.  McHutchison JG. The role of genetic markers in hepatitis C 
virus therapy: a major step for individualized care. Liver Int. 
2011;31(Suppl 1):29-35.
14.  Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Saka-
moto N, et al. Genome-wide association of IL28B with response 
to pegylated interferon-alpha and ribavirin therapy for chronic 
hepatitis C. Nat Genet. 2009;41(10):1105-9.
15.  Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. Pegylated 
interferon-alpha-2a plus ribavirin for treatment-naive Asian pa-
tients with hepatitis C virus genotype 1 infection: a multicenter, 
randomized controlled trial. Clin Infect Dis. 2008;47(10):1260-9.
16.  Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, 
et al. Interleukin-28B polymorphism improves viral kinetics 
and is the strongest pretreatment predictor of sustained viro-
logic response in genotype 1 hepatitis C virus. Gastroenterology. 
2010;139(1):120-9 e18.
17.  Sarrazin C, Schwendy S, Moeller B, Dikopoulos N, Buggisch P, 
Encke J, et al. Completely individualized treatment durations 
with peginterferon-alfa-2b and ribavirin in HCV genotype 1-in-
fected patients and importance of IL28B genotype (INDIV-2 
study). Hepatology. 2010;52(Suppl S1):384A.
18.  Stattermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scher-
zer TM, et al. Impact of IL28B genotype on the early and sustained 
virologic response in treatment-naive patients with chronic hep-
atitis C. Clin Gastroenterol Hepatol. 2011;9(4):344-50 e2.
19.  Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel 
K, et al. An IL28B polymorphism determines treatment response 
of hepatitis C virus genotype 2 or 3 patients who do not achieve a 
rapid virologic response. Gastroenterology. 2010;139(3):821-7, 7 e1.
20.  Kawaoka R, Ochi H, Hiraga N, Tsuge M, Imamura M, Kawakami 
Y, et al. Predictive value of IL-28 polymorphism of effect of inter-
feron therapy in patients with genotype 2a and 2b chronic hepa-
titis C. Hepatology. 2010;52(Suppl S1):701A.
21.  Lagging M, Askarieh G, Negro F, Bibert S, Soderholm J, Westin J, 
et al. Response prediction in chronic hepatitis C by assessment 
of IP-10 and IL28B-related single nucleotide polymorphisms. 
PLoS One. 2011;6(2):e17232.